Valley is aware of the nationwide supply disruption of IV fluid solution due to Hurricane Helene, and wants to reassure the community that steps have been taken to ensure the situation will have no negative impact on our patients and the community.
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
NCT04752813